{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T23:04:39Z","timestamp":1789167879326,"version":"build-2803163510"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-06851-8","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T12:45:43Z","timestamp":1751373943000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Predicting cisplatin response in cholangiocarcinoma patients using chromosome pattern and related gene expression"],"prefix":"10.1038","volume":"15","author":[{"given":"Sutheemon","family":"Techa-ay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasithorn","family":"Watcharadetwittaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raksawan","family":"Deenonpoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kitti","family":"Intuyod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waleeporn","family":"Kaewlert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anchalee","family":"Techasen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Watcharin","family":"Loilome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poramate","family":"Klanrit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manida","family":"Suksawat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwanjira","family":"Chaleekan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirinya","family":"Sitthirak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malinee","family":"Thanee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"6851_CR1","doi-asserted-by":"publisher","unstructured":"Virani, S. et al. National and subnational Population-Based incidence of Cancer in thailand: assessing cancers with the highest burdens. Cancers (Basel). 9 https:\/\/doi.org\/10.3390\/cancers9080108 (2017).","DOI":"10.3390\/cancers9080108"},{"key":"6851_CR2","doi-asserted-by":"publisher","first-page":"e201","DOI":"10.1371\/journal.pmed.0040201","volume":"4","author":"B Sripa","year":"2007","unstructured":"Sripa, B. et al. Liver fluke induces cholangiocarcinoma. PLoS Med. 4, e201. https:\/\/doi.org\/10.1371\/journal.pmed.0040201 (2007).","journal-title":"PLoS Med."},{"key":"6851_CR3","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","volume":"17","author":"JM Banales","year":"2020","unstructured":"Banales, J. M. et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat. Rev. Gastroenterol. Hepatol. 17, 557\u2013588. https:\/\/doi.org\/10.1038\/s41575-020-0310-z (2020).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"6851_CR4","doi-asserted-by":"publisher","unstructured":"Chen, S. H. & Chang, J. Y. New insights into mechanisms of cisplatin resistance: from tumor cell to microenvironment. Int. J. Mol. Sci. 20 https:\/\/doi.org\/10.3390\/ijms20174136 (2019).","DOI":"10.3390\/ijms20174136"},{"key":"6851_CR5","doi-asserted-by":"publisher","first-page":"408","DOI":"10.3978\/j.issn.2078-6891.2014.072","volume":"5","author":"JE Rogers","year":"2014","unstructured":"Rogers, J. E. et al. Second-line systemic treatment for advanced cholangiocarcinoma. J. Gastrointest. Oncol. 5, 408\u2013413. https:\/\/doi.org\/10.3978\/j.issn.2078-6891.2014.072 (2014).","journal-title":"J. Gastrointest. Oncol."},{"key":"6851_CR6","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.omto.2020.05.010","volume":"17","author":"F Kou","year":"2020","unstructured":"Kou, F., Wu, L., Ren, X. & Yang, L. Chromosome abnormalities: new insights into their clinical significance in Cancer. Mol. Ther. Oncolytics. 17, 562\u2013570. https:\/\/doi.org\/10.1016\/j.omto.2020.05.010 (2020).","journal-title":"Mol. Ther. Oncolytics"},{"key":"6851_CR7","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/s41467-020-14286-0","volume":"11","author":"A Shukla","year":"2020","unstructured":"Shukla, A. et al. Chromosome arm aneuploidies shape tumour evolution and drug response. Nat. Commun. 11, 449. https:\/\/doi.org\/10.1038\/s41467-020-14286-0 (2020).","journal-title":"Nat. Commun."},{"key":"6851_CR8","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/s41419-020-03218-x","volume":"11","author":"W Li","year":"2020","unstructured":"Li, W. et al. Targeting the NCOA3-SP1-TERT axis for tumor growth in hepatocellular carcinoma. Cell. Death Dis. 11, 1011. https:\/\/doi.org\/10.1038\/s41419-020-03218-x (2020).","journal-title":"Cell. Death Dis."},{"key":"6851_CR9","doi-asserted-by":"publisher","unstructured":"Timmerman, D. M. et al. Chromosome 3p25.3 gain is associated with cisplatin resistance and is an independent predictor of poor outcome in male malignant germ cell tumors. 40, 3077\u20133087, (2022). https:\/\/doi.org\/10.1200\/jco.21.02809","DOI":"10.1200\/jco.21.02809"},{"key":"6851_CR10","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/path.2574","volume":"219","author":"C Marchio","year":"2009","unstructured":"Marchio, C. et al. Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis. J. Pathol. 219, 16\u201324. https:\/\/doi.org\/10.1002\/path.2574 (2009).","journal-title":"J. Pathol."},{"key":"6851_CR11","doi-asserted-by":"publisher","unstructured":"Wilhelm, A. B. et al. Pediatric combined hepatocellular-cholangiocarcinoma (cHCC-CC) with neuroendocrine features: distinguishing genetic alterations detected by chromosomal microarray. Diagn. Pathol. 18 https:\/\/doi.org\/10.1186\/s13000-023-01305-z (2023).","DOI":"10.1186\/s13000-023-01305-z"},{"key":"6851_CR12","doi-asserted-by":"publisher","first-page":"7829","DOI":"10.18632\/oncotarget.6953","volume":"7","author":"NV Litviakov","year":"2016","unstructured":"Litviakov, N. V. et al. Deletions of multidrug resistance gene loci in breast cancer leads to the down-regulation of its expression and predict tumor response to neoadjuvant chemotherapy. Oncotarget 7, 7829\u20137841. https:\/\/doi.org\/10.18632\/oncotarget.6953 (2016).","journal-title":"Oncotarget"},{"key":"6851_CR13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2147\/IJGM.S186854","volume":"12","author":"M Alsaleh","year":"2019","unstructured":"Alsaleh, M. et al. Cholangiocarcinoma: a guide for the nonspecialist. Int. J. Gen. Med. 12, 13\u201323. https:\/\/doi.org\/10.2147\/IJGM.S186854 (2019).","journal-title":"Int. J. Gen. Med."},{"key":"6851_CR14","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1186\/s12885-021-08247-z","volume":"21","author":"C Tawarungruang","year":"2021","unstructured":"Tawarungruang, C. et al. Survival after surgery among patients with cholangiocarcinoma in Northeast Thailand according to anatomical and morphological classification. BMC Cancer. 21, 497. https:\/\/doi.org\/10.1186\/s12885-021-08247-z (2021).","journal-title":"BMC Cancer"},{"key":"6851_CR15","doi-asserted-by":"publisher","unstructured":"Ram\u00edrez-Merino, N. Chemotherapy for cholangiocarcinoma: an update. World J. Gastrointest. Oncol. 5 https:\/\/doi.org\/10.4251\/wjgo.v5.i7.171 (2013).","DOI":"10.4251\/wjgo.v5.i7.171"},{"key":"6851_CR16","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1159\/000531458","volume":"13","author":"C Yoo","year":"2024","unstructured":"Yoo, C., Hyung, J. & Chan, S. L. Recent advances in systemic therapy for advanced intrahepatic cholangiocarcinoma. Liver Cancer. 13, 119\u2013135. https:\/\/doi.org\/10.1159\/000531458 (2024).","journal-title":"Liver Cancer"},{"key":"6851_CR17","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jhep.2022.09.004","volume":"78","author":"JJ Harding","year":"2023","unstructured":"Harding, J. J., Khalil, D. N. & Fabris, L. Abou-Alfa, G. K. Rational development of combination therapies for biliary tract cancers. J. Hepatol. 78, 217\u2013228. https:\/\/doi.org\/10.1016\/j.jhep.2022.09.004 (2023).","journal-title":"J. Hepatol."},{"key":"6851_CR18","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley, R. K. et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 401, 1853\u20131865. https:\/\/doi.org\/10.1016\/S0140-6736(23)00727-4 (2023).","journal-title":"Lancet"},{"key":"6851_CR19","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1186\/s12885-024-12225-6","volume":"24","author":"M Niger","year":"2024","unstructured":"Niger, M. et al. A phase II\/III randomized clinical trial of cisplatin plus gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patients with resectable biliary tract cancers (BTC) at high risk for recurrence: PURITY study. BMC Cancer. 24, 436. https:\/\/doi.org\/10.1186\/s12885-024-12225-6 (2024).","journal-title":"BMC Cancer"},{"key":"6851_CR20","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3322\/caac.21759","volume":"73","author":"D Moris","year":"2023","unstructured":"Moris, D. et al. Advances in the treatment of intrahepatic cholangiocarcinoma: an overview of the current and future therapeutic landscape for clinicians. CA Cancer J. Clin. 73, 198\u2013222. https:\/\/doi.org\/10.3322\/caac.21759 (2023).","journal-title":"CA Cancer J. Clin."},{"key":"6851_CR21","doi-asserted-by":"crossref","unstructured":"Hoffman, R. M., Jung, P. S., Kim, M. B. & Nam, J. H. in 3D Sponge-Matrix Histoculture: Methods and Protocols (ed Robert M. Hoffman) 73\u201381Springer New York, (2018).","DOI":"10.1007\/978-1-4939-7745-1_8"},{"key":"6851_CR22","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1097\/MOG.0b013e3283523c7e","volume":"28","author":"JB Andersen","year":"2012","unstructured":"Andersen, J. B. & Thorgeirsson, S. S. Genetic profiling of intrahepatic cholangiocarcinoma. Curr. Opin. Gastroenterol. 28, 266\u2013272. https:\/\/doi.org\/10.1097\/MOG.0b013e3283523c7e (2012).","journal-title":"Curr. Opin. Gastroenterol."},{"key":"6851_CR23","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1158\/0008-5472.CAN-23-3298","volume":"84","author":"H Liao","year":"2024","unstructured":"Liao, H. et al. Whole-Genome DNA methylation profiling of intrahepatic cholangiocarcinoma reveals prognostic subtypes with distinct biological drivers. Cancer Res. 84, 1747\u20131763. https:\/\/doi.org\/10.1158\/0008-5472.CAN-23-3298 (2024).","journal-title":"Cancer Res."},{"key":"6851_CR24","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1038\/s41467-022-30708-7","volume":"13","author":"Y Zhang","year":"2022","unstructured":"Zhang, Y. et al. The genomic landscape of cholangiocarcinoma reveals the disruption of post-transcriptional modifiers. Nat. Commun. 13, 3061. https:\/\/doi.org\/10.1038\/s41467-022-30708-7 (2022).","journal-title":"Nat. Commun."},{"key":"6851_CR25","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1006\/jsre.1999.5615","volume":"1","author":"SA Ahrendt","year":"1999","unstructured":"Ahrendt, S. A. et al. Chromosome 9p21 loss and p16 inactivation in primary sclerosing cholangitis-associated cholangiocarcinoma. J. Surg. Res. 1, 88\u201393. https:\/\/doi.org\/10.1006\/jsre.1999.5615 (1999).","journal-title":"J. Surg. Res."},{"key":"6851_CR26","doi-asserted-by":"publisher","first-page":"pbad030","DOI":"10.1093\/pcmedi\/pbad030","volume":"6","author":"Y Jiang","year":"2023","unstructured":"Jiang, Y. et al. Loss of chromosome 9p21 is associated with a poor prognosis in adenosquamous carcinoma of the pancreas. Precis Clin. Med. 6, pbad030. https:\/\/doi.org\/10.1093\/pcmedi\/pbad030 (2023).","journal-title":"Precis Clin. Med."},{"key":"6851_CR27","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1053\/j.gastro.2013.01.001","volume":"144","author":"D Sia","year":"2013","unstructured":"Sia, D. et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology 144, 829\u2013840. https:\/\/doi.org\/10.1053\/j.gastro.2013.01.001 (2013).","journal-title":"Gastroenterology"},{"key":"6851_CR28","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1200\/JCO.21.02809","volume":"40","author":"DM Timmerman","year":"2022","unstructured":"Timmerman, D. M. et al. Chromosome 3p25.3 gain is associated with cisplatin resistance and is an independent predictor of poor outcome in male malignant germ cell tumors. J. Clin. Oncol. 40, 3077\u20133087. https:\/\/doi.org\/10.1200\/JCO.21.02809 (2022).","journal-title":"J. Clin. Oncol."},{"key":"6851_CR29","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.4143\/crt.2022.1450","volume":"55","author":"SH Lee","year":"2023","unstructured":"Lee, S. H. et al. ARID1A mutation from targeted Next-Generation sequencing predicts primary resistance to gemcitabine and cisplatin chemotherapy in advanced biliary tract Cancer. Cancer Res. Treat. 55, 1291\u20131302. https:\/\/doi.org\/10.4143\/crt.2022.1450 (2023).","journal-title":"Cancer Res. Treat."},{"key":"6851_CR30","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1186\/s12911-021-01688-3","volume":"21","author":"S Han","year":"2021","unstructured":"Han, S., Williamson, B. D. & Fong, Y. Improving random forest predictions in small datasets from two-phase sampling designs. BMC Med. Inf. Decis. Mak. 21, 322. https:\/\/doi.org\/10.1186\/s12911-021-01688-3 (2021).","journal-title":"BMC Med. Inf. Decis. Mak."},{"key":"6851_CR31","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.it.2022.03.003","volume":"43","author":"P Spiliopoulou","year":"2022","unstructured":"Spiliopoulou, P. et al. All is not lost: learning from 9p21 loss in cancer. Trends Immunol. 43, 379\u2013390. https:\/\/doi.org\/10.1016\/j.it.2022.03.003 (2022).","journal-title":"Trends Immunol."},{"key":"6851_CR32","doi-asserted-by":"publisher","unstructured":"Lira, M. C. et al. NCoA3 upregulation in breast cancer\u2013associated adipocytes elicits an inflammatory profile. Oncol. Rep. 49 https:\/\/doi.org\/10.3892\/or.2023.8542 (2023).","DOI":"10.3892\/or.2023.8542"},{"key":"6851_CR33","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/modpathol.2010.217","volume":"24","author":"JK Habermann","year":"2011","unstructured":"Habermann, J. K. et al. Genomic instability and oncogene amplifications in colorectal adenomas predict recurrence and synchronous carcinoma. Mod. Pathol. 24, 542\u2013555. https:\/\/doi.org\/10.1038\/modpathol.2010.217 (2011).","journal-title":"Mod. Pathol."},{"key":"6851_CR34","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s12020-021-02819-6","volume":"75","author":"Y Li","year":"2022","unstructured":"Li, Y. et al. NCOA3 is a critical oncogene in thyroid cancer via the modulation of major signaling pathways. Endocrine 75, 149\u2013158. https:\/\/doi.org\/10.1007\/s12020-021-02819-6 (2022).","journal-title":"Endocrine"},{"key":"6851_CR35","doi-asserted-by":"publisher","first-page":"100111","DOI":"10.1016\/j.phyplu.2021.100111","volume":"1","author":"JM Ku","year":"2021","unstructured":"Ku, J. M. et al. SH003 overcomes drug resistance and immune checkpoints by inhibiting JAK-STAT3 signaling in MCF7\/ADR cells. Phytomedicine Plus. 1, 100111. https:\/\/doi.org\/10.1016\/j.phyplu.2021.100111 (2021).","journal-title":"Phytomedicine Plus"},{"key":"6851_CR36","doi-asserted-by":"publisher","first-page":"e2463","DOI":"10.1038\/cddis.2016.367","volume":"7","author":"X Ao","year":"2016","unstructured":"Ao, X. et al. Decreased expression of microRNA-17 and microRNA-20b promotes breast cancer resistance to taxol therapy by upregulation of NCOA3. Cell. Death Dis. 7, e2463. https:\/\/doi.org\/10.1038\/cddis.2016.367 (2016).","journal-title":"Cell. Death Dis."},{"key":"6851_CR37","doi-asserted-by":"publisher","first-page":"3386","DOI":"10.1038\/onc.2010.90","volume":"29","author":"Y Xu","year":"2010","unstructured":"Xu, Y. et al. Overexpression of transcriptional coactivator AIB1 promotes hepatocellular carcinoma progression by enhancing cell proliferation and invasiveness. Oncogene 29, 3386\u20133397. https:\/\/doi.org\/10.1038\/onc.2010.90 (2010).","journal-title":"Oncogene"},{"key":"6851_CR38","doi-asserted-by":"publisher","first-page":"152820","DOI":"10.1016\/j.prp.2020.152820","volume":"216","author":"JY Hong","year":"2020","unstructured":"Hong, J. Y. et al. TPK1 as a predictive marker for the anti-tumour effects of Simvastatin in gastric cancer. Pathol. Res. Pract. 216, 152820. https:\/\/doi.org\/10.1016\/j.prp.2020.152820 (2020).","journal-title":"Pathol. Res. Pract."},{"key":"6851_CR39","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/2049-3002-1-16","volume":"1","author":"JA Zastre","year":"2013","unstructured":"Zastre, J. A., Sweet, R. L., Hanberry, B. S. & Ye, S. Linking vitamin B1 with cancer cell metabolism. Cancer Metabolism. 1, 16. https:\/\/doi.org\/10.1186\/2049-3002-1-16 (2013).","journal-title":"Cancer Metabolism"},{"key":"6851_CR40","doi-asserted-by":"publisher","first-page":"35422","DOI":"10.18632\/oncotarget.26259","volume":"9","author":"HC Jonus","year":"2018","unstructured":"Jonus, H. C. et al. The adaptive regulation of thiamine pyrophosphokinase-1 facilitates malignant growth during supplemental thiamine conditions. Oncotarget 9, 35422\u201335438. https:\/\/doi.org\/10.18632\/oncotarget.26259 (2018).","journal-title":"Oncotarget"},{"key":"6851_CR41","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.canlet.2014.11.058","volume":"357","author":"S Kim","year":"2015","unstructured":"Kim, S. et al. Bioinformatic and metabolomic analysis reveals miR-155 regulates thiamine level in breast cancer. Cancer Lett. 357, 488\u2013497. https:\/\/doi.org\/10.1016\/j.canlet.2014.11.058 (2015).","journal-title":"Cancer Lett."},{"key":"6851_CR42","doi-asserted-by":"publisher","first-page":"4285","DOI":"10.1182\/blood-2011-03-341388","volume":"118","author":"B Kigel","year":"2011","unstructured":"Kigel, B., Rabinowicz, N., Varshavsky, A., Kessler, O. & Neufeld, G. Plexin-A4 promotes tumor progression and tumor angiogenesis by enhancement of VEGF and bFGF signaling. Blood 118, 4285\u20134296. https:\/\/doi.org\/10.1182\/blood-2011-03-341388 (2011).","journal-title":"Blood"},{"key":"6851_CR43","doi-asserted-by":"publisher","unstructured":"Toledano, S. & Neufeld, G. Plexins as regulators of Cancer cell proliferation, migration, and invasivity. Cancers (Basel). 15 https:\/\/doi.org\/10.3390\/cancers15164046 (2023).","DOI":"10.3390\/cancers15164046"},{"key":"6851_CR44","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1002\/humu.21017","volume":"30","author":"A Balakrishnan","year":"2009","unstructured":"Balakrishnan, A. et al. Molecular profiling of the plexinome in melanoma and pancreatic cancer. Hum. Mutat. 30, 1167\u20131174. https:\/\/doi.org\/10.1002\/humu.21017 (2009).","journal-title":"Hum. Mutat."},{"issue":"Suppl 1","key":"6851_CR45","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/hep.31394","volume":"73","author":"S Caruso","year":"2021","unstructured":"Caruso, S., O\u2019Brien, D. R., Cleary, S. P., Roberts, L. R. & Zucman-Rossi, J. Genetics of hepatocellular carcinoma: approaches to explore molecular diversity. Hepatology 73 (Suppl 1), 14\u201326. https:\/\/doi.org\/10.1002\/hep.31394 (2021).","journal-title":"Hepatology"},{"key":"6851_CR46","doi-asserted-by":"publisher","first-page":"065004","DOI":"10.1088\/1478-3975\/9\/6\/065004","volume":"9","author":"SV Liu","year":"2012","unstructured":"Liu, S. V. et al. Genomic analysis and selected molecular pathways in rare cancers. Phys. Biol. 9, 065004. https:\/\/doi.org\/10.1088\/1478-3975\/9\/6\/065004 (2012).","journal-title":"Phys. Biol."},{"key":"6851_CR47","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1152\/physrev.00064.2017","volume":"98","author":"A Caron","year":"2018","unstructured":"Caron, A., Briscoe, D. M., Richard, D. & Laplante, M. DEPTOR at the Nexus of cancer, metabolism, and immunity. Physiol. Rev. 98, 1765\u20131803. https:\/\/doi.org\/10.1152\/physrev.00064.2017 (2018).","journal-title":"Physiol. Rev."},{"key":"6851_CR48","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/ng.876","volume":"43","author":"D Miki","year":"2011","unstructured":"Miki, D. et al. Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers. Nat. Genet. 43, 797\u2013800. https:\/\/doi.org\/10.1038\/ng.876 (2011).","journal-title":"Nat. Genet."},{"key":"6851_CR49","doi-asserted-by":"publisher","first-page":"D672","DOI":"10.1093\/nar\/gkae909","volume":"53","author":"M Kanehisa","year":"2025","unstructured":"Kanehisa, M., Furumichi, M., Sato, Y., Matsuura, Y. & Ishiguro-Watanabe, M. KEGG: biological systems database as a model of the real world. Nucleic Acids Res. 53, D672\u2013D677. https:\/\/doi.org\/10.1093\/nar\/gkae909 (2025).","journal-title":"Nucleic Acids Res."},{"key":"6851_CR50","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1002\/pro.3715","volume":"28","author":"M Kanehisa","year":"2019","unstructured":"Kanehisa, M. Toward Understanding the origin and evolution of cellular organisms. Protein Sci. 28, 1947\u20131951. https:\/\/doi.org\/10.1002\/pro.3715 (2019).","journal-title":"Protein Sci."},{"key":"6851_CR51","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa, M. & Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27\u201330. https:\/\/doi.org\/10.1093\/nar\/28.1.27 (2000).","journal-title":"Nucleic Acids Res."},{"key":"6851_CR52","doi-asserted-by":"publisher","first-page":"e0222140","DOI":"10.1371\/journal.pone.0222140","volume":"14","author":"M Suksawat","year":"2019","unstructured":"Suksawat, M. et al. In vitro and molecular chemosensitivity in human cholangiocarcinoma tissues. PLoS One. 14, e0222140. https:\/\/doi.org\/10.1371\/journal.pone.0222140 (2019).","journal-title":"PLoS One"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06851-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06851-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06851-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T12:45:45Z","timestamp":1751373945000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06851-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6851"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-06851-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"3 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The methods used in this study follow the guidelines of the Declaration of Helsinki and ICH Good Clinical Practice (ICH GCP) guidelines. This study was approved by The Ethics Committee for Human Research, Khon Kaen University, Thailand and signed informed consent was obtained from all patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"20420"}}